- Home
- INSM vs ICLR Comparison
INSM vs ICLR Comparison
Compare INSM & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- ICLR
- Stock Information
- Founded
- INSM 1988
- ICLR 1990
- Country
- INSM United States
- ICLR Ireland
- Employees
- INSM N/A
- ICLR N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- INSM Health Care
- ICLR Health Care
- Exchange
- INSM Nasdaq
- ICLR Nasdaq
- Market Cap
- INSM 12.6B
- ICLR 11.4B
- IPO Year
- INSM 2000
- ICLR 1998
- Fundamental
- Price
- INSM $69.73
- ICLR $130.28
- Analyst Decision
- INSM Strong Buy
- ICLR Buy
- Analyst Count
- INSM 17
- ICLR 12
- Target Price
- INSM $95.93
- ICLR $204.18
- AVG Volume (30 Days)
- INSM 2.3M
- ICLR 1.6M
- Earning Date
- INSM 05-08-2025
- ICLR 07-23-2025
- Dividend Yield
- INSM N/A
- ICLR N/A
- EPS Growth
- INSM N/A
- ICLR 11.53
- EPS
- INSM N/A
- ICLR 9.19
- Revenue
- INSM $381,030,000.00
- ICLR $8,192,621,999.00
- Revenue This Year
- INSM $29.15
- ICLR N/A
- Revenue Next Year
- INSM $115.02
- ICLR $2.34
- P/E Ratio
- INSM N/A
- ICLR $14.18
- Revenue Growth
- INSM 20.77
- ICLR N/A
- 52 Week Low
- INSM $53.69
- ICLR $125.10
- 52 Week High
- INSM $84.91
- ICLR $347.72
- Technical
- Relative Strength Index (RSI)
- INSM 53.15
- ICLR 39.23
- Support Level
- INSM $65.56
- ICLR $125.10
- Resistance Level
- INSM $68.74
- ICLR $132.96
- Average True Range (ATR)
- INSM 2.41
- ICLR 4.34
- MACD
- INSM 0.42
- ICLR 0.79
- Stochastic Oscillator
- INSM 76.91
- ICLR 29.63
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.